Skip to main content
TipRanks
Go Ultimate75% OFF

SiriusPoint (3XPA) AI Stock Analysis

0 Followers
DE:3XPA

SiriusPoint

(Frankfurt:3XPA)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Underwriting profitabilityStrong underwriting profitability and operating returns above the 12%–15% target indicate that SiriusPoint is converting premium volume into attractive earnings. Maintaining a combined ratio near 90% supports capital generation and reinforces confidence in the company’s core insurance model over the next several quarters.
Negative Factors
Inconsistent cash generationAlthough operating cash flow has improved, its sharp year-to-year swings reduce predictability and make earnings quality harder to assess in a reinsurance business. Very low cash-flow-to-debt coverage also limits near-term debt paydown capacity, leaving less internally generated liquidity for adverse developments.

SiriusPoint (3XPA) vs. iShares MSCI Germany ETF (EWG)

-10%0%10%20%30%40%50%DE:3XPA+40.48%EWG+7.62%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 2.98B
Dividend Yield
―
Average Volume (3M)
43
Price to Earnings (P/E)
6.2
Beta (1Y)
0.12
Revenue Growth
12.45%
EPS Growth
155.41%
Country
Germany
Employees
1,068
Sector
Financial
Sector Strength
68
Industry
Insurance - Reinsurance

SiriusPoint Business Overview & Revenue Model

Company Description

SiriusPoint Ltd. provides multi-line reinsurance and insurance products and services worldwide. It operates in four segments: Global P&C Programs, Global Reinsurance, Global Accident & Health, and London Market Specialty. Global P&C Programs segment...

SiriusPoint Earnings Call Summary

Earnings Call Date:Nov 05, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Feb 25, 2027
Earnings Call SentimentPositive

The call was strongly positive. SiriusPoint reported attractive underwriting margins, operating returns above its 12% to 15% target, premium and earnings growth, favorable reserve development, strong capital and liquidity, and an encouraging growth pipeline. The LPT was presented as a major step in reducing legacy uncertainty and releasing capital, although it carries an approximately $60 million day-one cost, requires regulatory approval, and leaves a claims-administration tail. Competitive pricing, lower year-to-date reinsurance premiums, selected program nonrenewals, and pressure in property catastrophe and other lines were acknowledged, but management emphasized disciplined portfolio management and continued opportunities for profitable growth.

Positive Updates

Strong Third-Quarter Profitability and Returns
SiriusPoint reported a core combined ratio of 90.1% in the third quarter, underwriting income of $76 million, operating net income of $103 million, and operating return on equity of 17.6%, above the company's 12% to 15% target range.

Negative Updates

Loss Portfolio Transfer Upfront Cost
The expected day-one cost of the LPT is approximately $60 million.

Company Guidance

Management stated a 12% to 15% ROE target range and said the LPT reinforces the company's ability and confidence to meet or outperform that range going forward; A&H premiums are expected to return to low single digit growth in the fourth quarter, specialty P&C premiums are expected to be modestly lower year over year in the fourth quarter, with growth expected to resume in 2027, and the 2027 pipeline remains encouraging. Within US medical, excess of loss, rate expectations are in excess of 20%, while major airlines are expected to see double digit rate increases during the fourth quarter renewal season; property catastrophe reinsurance, approximately 4% of the portfolio, is expected to face continued pricing pressure. Claims administration costs are expected to be around $15, $16 million a year and come down over roughly a 3-year period, with about a 3-year, 2.5- to 3-year, tail; the LPT has an expected day 1 cost of approximately $60 million and is expected to increase the BSCR ratio by approximately 20 points on a pro-forma basis upon close. Management said it would ideally complete the LPT in Q4, though it could slip into Q1, and expects to restart repurchases, with at least whether it is a meaningful component or all of the remaining authorization executed between now and the end of the year, with a component potentially trickling over into 1 queue.

SiriusPoint Risk Analysis

SiriusPoint disclosed 62 risk factors in its most recent earnings report. SiriusPoint reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

SiriusPoint Peers Comparison

Overall Rating

UnderperformOutperform
Sector (68)

Financial Indicators

DE:3XPA against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HGHG85Outperform$3.79B7.1623.92%―18.05%22.42%
SKWDSKWD80Outperform$2.82B14.4616.06%―35.25%25.99%
IGICIGIC76Outperform$1.01B10.0115.27%5.97%1.96%―
RNRRNR76Outperform$14.23B10.0513.52%0.46%-21.18%-3.27%
Sector *68Neutral$18.00B11.429.92%3.81%9.73%1.22%
EGEG65Neutral$15.72B9.0512.52%1.88%-8.72%250.85%

* Financial Sector Average

Performance Comparison

0%20%40%60%DE:3XPAEGRNRIGICSKWDHGDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:3XPA and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:3XPASiriuspoint Ltd23.606.7039.64%
EGEverest Group, Ltd.420.04122.2841.07%
RNRRenaissancere346.8186.7533.36%
IGICInternational General Insurance Holdings Ltd.23.901.898.58%
SKWDSkyward Specialty Insurance Group, Inc.63.5316.9336.33%
HGHamilton Insurance Group, Ltd. Class B38.3214.2759.31%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.